Therapeutic Plasma Exchange in Glucocorticosteroid-Unresponsive Patients With Clinically Isolated Syndrome

Therapeutic Apheresis and Dialysis

Volumn 18, Issue 5, 2014, Pages 489-496

  Ehler, Johannes ^a   Koball, Sebastian ^a   Sauer, Martin ^a   Hickstein, Heiko ^a   Mitzner, Steffen ^a   Benecke, Reiner ^a   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Apheresis; Escalation therapy; Multiple sclerosis; Neuroimmunology; Steroid refractory

Indexed keywords

GLUCOCORTICOID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEMYELINATING DISEASE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; THERAPEUTIC PLASMA EXCHANGE; YOUNG ADULT; APHERESIS; DEMYELINATING DISEASES; DISABILITY; PATHOPHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; BLOOD COMPONENT REMOVAL; DEMYELINATING DISEASES; DISABILITY EVALUATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; PLASMA EXCHANGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84909967103     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12176     Document Type: Article

References (37)

1. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol 2005;4:341-348.
2. McDonald WI, Comptson A, Edan G etal. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
3. Kocer B, Unal T, Nazliel B etal. Evaluating sub-clinical cognitive dysfunction and event-related potentials (P300) in clinically isolated syndrome. Neurol Sci 2008;29:435-444.
4. Tintore M, Rovira A, Brieva L etal. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Mult Scler 2001;7:359-363.
5. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-288.
6. Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1720-1725.
7. Fuhr P, Kappos L. Evoked potentials for evaluation of multiple sclerosis. Clin Neurophysiol 2001;112:2185-2189.
8. Goldman MD, Motl RW, Rudick RA. Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord 2010;3:229-239.
9. Sellebjerg F, Barnes D, Filippini G etal. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 2005;12:939-946.
10. Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008;255:1449-1463.
11. Khatri BO. Therapeutic apheresis in multiple sclerosis and other central nervous system disorders. Ther Apher 2000;4:263-270.
12. Chhibber V, Weinstein R. Evidence-based review of therapeutic plasma exchange in neurological disorders. Semin Dial 2012;25:132-139.
13. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143-146.
14. Meca-Lallana JE, Hernandez-Clares R, Leon-Hernandez A, Genoves Aleixandre A, Cacho Perez M, Martin-Fernandez JJ. Plasma exchange for steroid-refractory relapses in multiple sclerosis: an observational, MRI pilot study. Clin Ther 2013;35:474-485.
15. Trebst C, Reising A, Kielstein JT, Hafer C, Stangel M. Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2009;28:108-115.
16. Schroeder A, Fischer M, Meyer C etal. Therapeutic plasma exchange for steroid unresponsive multiple sclerosis relapses-a long-term follow-up observation including 35 patients. Akt Neurol 2009;36:105-110.
17. Jamshidian A, Gharagozloo M. Can plasma exchange therapy induce regulatory T lymphocytes in multiple sclerosis patients? Clin Exp Immunol 2012;168:75-77.
18. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;76:294-300.
19. Szczepiorkowski ZM, Winters JL, Bandarenko N etal. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010;25:83-177.
20. Greenberg BM, Khatri BO, Kramer JF. Current and emerging multiple sclerosis therapeutics. Continuum (Minneap Minn) 2010;16:58-77.
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
22. Hommes OR, Sorensen PS, Fazekas F etal. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004;364:1149-1156.
23. Sastre-Garriga J, Tintore M, Rovira A etal. Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. Mult Scler 2003;9:39-43.
24. Sprenger KB, Huber K, Kratz W, Henze E. Nomograms for the prediction of patient's plasma volume in plasma exchange therapy from height, weight, and hematocrit. J Clin Apher 1987;3:185-190.
25. Kaplan AA. Toward the rational prescription of therapeutic plasma exchange: the kinetics of immunoglobulin removal. Semin Dial 1992;5:227-229.
26. Rieckmann P, Toyka KV, Bassetti C etal. Escalating immunotherapy of multiple sclerosis-new aspects and practical application. J Neurol 2004;251:1329-1339.
27. McLeod BC. Plasmapheresis in multiple sclerosis. J Clin Apher 2003;18:72-74.
28. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
29. Trebst C, Bronzlik P, Kielstein JT, Schmidt BM, Stangel M. Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2012;33:1-6.
30. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 1991;337:441-446.
31. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
32. Keegan M, Konig F, McClelland R etal. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366:579-582.
33. Matzke B, Metze C, Winkelmann A etal. Severe relapse of multiple sclerosis during plasma exchange treatment. Mult Scler 2011;17:759-762.
34. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-468.
35. Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 2008;4:384-398.
36. Llufriu S, Castillo J, Blanco Y etal. Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology 2009;73:949-953.
37. Weinshenker BG, O'Brien PC, Petterson TM etal. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-886.